Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
21 Results for "
advanced prostate cancer
" in MedChemExpress (MCE) Product Catalog:
Products (21)
21 Results for "advanced prostate cancer" in MCE Product Catalog:
4
Nuvisertib (TP-3654) is an orally active second-generation pan-PIM kinase inhibitor with Ki values of 5 nM, 239 nM, and 42 nM against PIM-1, PIM-2, and PIM-3, respectively. Nuvisertib inhibits JAK-independent inflammatory and survival signaling pathways, reduces the production of proinflammatory cytokines, restores apoptotic sensitivity, inhibits mTORC1, MYC, and TGF-β signaling pathways, and decreases the expression of fibrosis markers. Nuvisertib selectively impairs the transport function of ABCG2, resensitizes multidrug-resistant cancer cells to cytotoxic drugs, and overcomes JAK2 inhibitor resistance. Nuvisertib can be used in research related to myelofibrosis, renal cell carcinoma, multidrug-resistant cancer, advanced solid tumors, urothelial carcinoma, and prostate adenocarcinoma .
3
Target:
Research Areas:
BMS-986365 (CC-94676) is an orally active and selective targeted androgen receptor (AR) PROTAC degrader (DC50 of 10-40 nM). BMS-986365 is capable of inducing cereblon (CRBN) E3 ligase-dependent ubiquitination and degradation of the androgen receptor (AR), as well as various AR mutants. BMS-986365 shows no degradation of the close AR family members estrogen receptor (ER), progesterone receptor (PR), and glucocorticoid receptor (GR). BMS-986365 shows significant in vivo potency, degrading AR, inhibiting AR signaling, and restricting tumor growth in animal models of advanced prostate cancer. BMS-986365 can be used for the study of metastatic castration-resistant prostate cancer (mCRPC) .
1
1 Cited Publications
Synonyms: HBED-CC-PSMA
Research Areas:
PSMA-11 is a small molecule ligand that targets prostate-specific membrane antigen (PSMA) and has the ability to inhibit PSMA activity. PSMA-11 can be used to synthesize 68Ga-PSMA-11, a positron emission tomography (PET) tracer that can be used to image advanced prostate cancer .
Cat. No.: HY-P990635
Target:
Research Areas:
Cat. No.: HY-158498
Synonyms: FA2 N-linked oligosaccharide; F(6)A2 glycan
Target:
Research Areas:
Aldehyde Dehydrogenase Isobutyramide is an orally active liver alcohol dehydrogenase (LADH2) inhibitor. Isobutyramide inhibits ethanol metabolism and enhances differentiation-related gene expression, inducing cell cycle arrest and significantly reducing the growth rate of prostate cancer cells (LNCaP). Isobutyramide is promising for research of advanced prostate cancer .
Cat. No.: HY-13622
CAS No.: 220997-99-9
Synonyms: BN 80927
Target:
Research Areas:
Elomotecan hydrochloride (BN 80927) is an orally active, potent inhibitor of topoisomerases I and II and a homocamptothecin (hCPT) analogue. Elomotecan hydrochloride possesses a dual inhibitory mechanism: it acts as a topoisomerase I poison by stabilizing the DNA-enzyme complex while simultaneously serving as a catalytic inhibitor of topoisomerase II. Elomotecan hydrochloride is used in research concerning various advanced and multidrug-resistant (MDR) solid tumors (such as prostate, colon, and breast cancers) .
Cat. No.: HY-13622A
CAS No.: 220998-10-7
Synonyms: BN 80927 free base
Target:
Research Areas:
Elomotecan (BN 80927 free base) is an orally active, potent inhibitor of topoisomerases I and II and a homocamptothecin (hCPT) analogue. Elomotecan possesses a dual inhibitory mechanism: it acts as a topoisomerase I poison by stabilizing the DNA-enzyme complex while simultaneously serving as a catalytic inhibitor of topoisomerase II. Elomotecan is used in research concerning various advanced and multidrug-resistant (MDR) solid tumors (such as prostate, colon, and breast cancers) .
Cat. No.: HY-174908
Research Areas:
SJL2-1 is a PRMT5 inhibitor, with an IC50 of 1.56 μM. SJL2-1 suppresses proliferation, migration, and invasion in prostate cancer cells. SJL2-1 promotes apoptosis and blocks the cell cycle at the G0/G1 phase. SJL2-1 can target the binding of PRMT5 in cells and inhibit the methylation and expression of the androgen receptor. SJL2-1 can be used for the study of early androgen-sensitive prostate cancer and advanced castration-resistant prostate cancer (CRPC) .
Cat. No.: HY-175000
Research Areas:
L14-8 is a potent ferroptosis inducer. L14-8 promotes PLK1 degradation via ubiquitination, increasing TP53 phosphorylation to enhance SAT1 transcription, thereby triggering ferroptosis and cancer cell death. L14-8 can be used for the study of advanced prostate cancer .
Cat. No.: HY-175826
Research Areas:
USP30-IN-20 is an orally active USP30 inhibitor (Kd = 1.61 μM, IC50 = 12.8 μM). USP30-IN-20 induces ferroptosis by promoting ubiquitination-mediated degradation of GPX4. USP30-IN-20 inhibits the proliferation, migration, invasion, and stemness of prostate cancer cells. USP30-IN-20 induces G0/G1 cell cycle arrest and ROS levels in prostate cancer cells. USP30-IN-20 exhibits significant anti-tumor efficacy in PC3 cell subcutaneous xenografts in mice. USP30-IN-20 can be used for the study of advanced prostate cancer .
Cat. No.: HY-118487A
CAS No.: 940061-39-2
Target:
Research Areas:
OB-24 free base is a compound that potently and selectively inhibits heme oxygenase 1 (HO-1) and has the potential to inhibit advanced prostate cancer. OB-24 significantly reduces protein carbonylation and the formation of reactive oxygen species by selectively inhibiting HO-1 activity in prostate cancer cells. OB-24 significantly inhibited cell proliferation in vitro and inhibited tumor growth and lymph node and lung metastasis in vivo. OB-24 exhibits powerful synergy when used in combination with Taxol .
Cat. No.: HY-151247
CAS No.: 2826273-90-7
Target:
Research Areas:
GnRH-R antagonist 1 (compound 21a) is an orally safe and membrane-permeable GnRH-R antagonist with high binding affinity (IC50=0.57 nM) and potent in vitro antagonistic activity (IC50=2.18 nM). GnRH-R antagonist 1 can be used in studies of advanced prostate cancer and premature LH peaks preventing .
Cat. No.: HY-123664
CAS No.: 68307-81-3
Synonyms: LY133314
Target:
Research Areas:
Trioxifene mesylate (LY133314) is an orally active and selective estrogen receptor (ER) modulator with human ERα IC50 of 203.49 nM and Ki of 20.84 nM. Trioxifene mesylate binds estradiol receptors, inhibits ERα-mediated gene expression, reduces circulating gonadotrophin levels. Trioxifene mesylate can be used for the research of advanced breast cancer and androgen-independent, metastatic prostatic adenocarcinoma .
Cat. No.: HY-13622B
Synonyms: BN 80927 TFA
Target:
Research Areas:
Elomotecan TFA (BN 80927 TFA) is an orally active, potent inhibitor of topoisomerases I and II and a homocamptothecin (hCPT) analogue. Elomotecan TFA possesses a dual inhibitory mechanism: it acts as a topoisomerase I poison by stabilizing the DNA-enzyme complex while simultaneously serving as a catalytic inhibitor of topoisomerase II. Elomotecan TFA is used in research concerning various advanced and multidrug-resistant (MDR) solid tumors (such as prostate, colon, and breast cancers) .
Cat. No.: HY-200492
CAS No.: 1017898-53-1
SU086 is a chalcone-derived HSP90 inhibitor. SU086 interacts with HSP90, reduces HSP90 protein levels, and suppresses glycolysis in prostate cancer cells. SU086 can be used in research related to advanced prostate cancer and castration-resistant prostate cancer (CRPC) .
Cat. No.: HY-135529
CAS No.: 63619-84-1
Synonyms: LY133314 free base
Target:
Research Areas:
Trioxifene (LY133314 free base) is an orally active and selective estrogen receptor (ER) modulator with human ERα IC50 of 203.49 nM and Ki of 20.84 nM. Trioxifene binds estradiol receptors, inhibits ERα-mediated gene expression, reduces circulating gonadotrophin levels. Trioxifene can be used for the research of advanced breast cancer and androgen-independent, metastatic prostatic adenocarcinoma .
Cat. No.: HY-187654
CAS No.: 27542-17-2
Erioflorin is a sesquiterpene lactone compound originally isolated from plants of the Asteraceae family (such as Eriophyllum confertiflorum and species of the Podanthus genus). Erioflorin acts as a selective β-TrCP1 modulator. Erioflorin induces cell apoptosis by increasing intracellular reactive oxygen species (ROS) production and decreasing mitochondrial membrane potential, inhibits the NF-κB signaling pathway by blocking the phosphorylation of IκBα, and prevents the ubiquitination and degradation of the tumor suppressor Pdcd4 by inhibiting the interaction between Pdcd4 and the E3 ubiquitin ligase β-TrCP1. Erioflorin can be used in research related to breast cancer, colon cancer, advanced prostate cancer, and Chagas disease .
Cat. No.: HY-158101R
CAS No.: 2446928-30-7
Synonyms: CC-94676 (Standard)
Research Areas:
BMS-986365 (Standard) is the analytical standard of BMS-986365 (HY-158101). This product is intended for research and analytical applications. BMS-986365 (CC-94676) is an orally active and selective targeted androgen receptor (AR) PROTAC degrader (DC50 of 10-40 nM). BMS-986365 is capable of inducing cereblon (CRBN) E3 ligase-dependent ubiquitination and degradation of the androgen receptor (AR), as well as various AR mutants. BMS-986365 shows no degradation of the close AR family members estrogen receptor (ER), progesterone receptor (PR), and glucocorticoid receptor (GR). BMS-986365 shows significant in vivo potency, degrading AR, inhibiting AR signaling, and restricting tumor growth in animal models of advanced prostate cancer. BMS-986365 can be used for the study of metastatic castration-resistant prostate cancer (mCRPC) .
Cat. No.: HY-101126A
CAS No.: 1418143-09-5
Synonyms: TP-3654 hydrochloride
Nuvisertib hydrochloride (TP-3654 hydrochloride) is an orally active second-generation pan-PIM kinase inhibitor with Ki values of 5 nM, 239 nM, and 42 nM against PIM-1, PIM-2, and PIM-3, respectively. Nuvisertib hydrochloride inhibits JAK-independent inflammatory and survival signaling pathways, reduces the production of proinflammatory cytokines, restores apoptotic sensitivity, inhibits mTORC1, MYC, and TGF-β signaling pathways, and decreases the expression of fibrosis markers. Nuvisertib hydrochloride selectively impairs the transport function of ABCG2, resensitizes multidrug-resistant cancer cells to cytotoxic drugs, and overcomes JAK2 inhibitor resistance. Nuvisertib hydrochloride can be used in research related to myelofibrosis, renal cell carcinoma, multidrug-resistant cancer, advanced solid tumors, urothelial carcinoma, and prostate adenocarcinoma .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
